Clinical Trials List
2018-08-18 - 2022-07-11
Phase III
Not yet recruiting3
Recruiting1
Terminated4
ICD-10C16.0
Malignant neoplasm of cardia
ICD-9151.9
Malignant neoplasm of stomach, unspecified
FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose-Finding in Phase 1
-
Trial Applicant
ICON Clinical Research Pte Ltd
-
Sponsor
Five Prime Therapeutics, Inc(FivePrime)
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Ming-Hung Tsai Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- Chang-Fang Chiu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Shang-Yin Wu Division of Hematology & Oncology
- 趙盈瑞 Division of Hematology & Oncology
- Yan-Shen Shan Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Audit
None
Co-Principal Investigator
- Yi-Ping Hung Division of Hematology & Oncology
- Chung-Pin Li Digestive System Department
- Ming-Huang Chen Division of Hematology & Oncology
- Rheun-Chuan Lee Division of Radiology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
Audit
None
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Yu-Li Su Division of Hematology & Oncology
- 吳佳哲 Division of Hematology & Oncology
- 陳彥豪 Division of Hematology & Oncology
- Shau-Hsuan Li Division of Hematology & Oncology
- Tai-Jan Chiu Division of Hematology & Oncology
- 劉建廷 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- 張平穎 Division of Hematology & Oncology
- 葉人華 Division of Hematology & Oncology
- 吳宜穎 Division of Hematology & Oncology
- 詹德全 Division of Hematology & Oncology
- 戴明燊 Division of Hematology & Oncology
- 陳佳宏 Division of Hematology & Oncology
- 陳宇欽 Division of Hematology & Oncology
- 黃子權 Division of Hematology & Oncology
- 蔡文銓 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Wei-Hong Cheng Division of Hematology & Oncology
- Yao-Yu Hsieh Division of Hematology & Oncology
- Tsu-Yi Chao Division of Hematology & Oncology
- YEN-HAO SU Division of Hematology & Oncology
- Huey-En Tzeng Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Wei-Wen Chang Division of Hematology & Oncology
- 方嘉郎 Division of Hematology & Oncology
- Mao-Chih Hsieh Division of Hematology & Oncology
- Chih-Ming Chou Division of Hematology & Oncology
- Chang-Yun Lu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
16 participants
-
Global
548 participants
